Swiss National Bank increased its stake in Aurora Cannabis Inc (NYSE:ACB) by 5.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,443,965 shares of the company’s stock after buying an additional 136,300 shares during the quarter. Swiss National Bank owned about 0.24% of Aurora Cannabis worth $22,117,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Norges Bank bought a new stake in shares of Aurora Cannabis during the fourth quarter worth $30,915,000. TD Asset Management Inc. bought a new stake in shares of Aurora Cannabis during the fourth quarter worth $16,657,000. Sumitomo Mitsui Trust Holdings Inc. lifted its position in shares of Aurora Cannabis by 1.8% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,357,247 shares of the company’s stock worth $21,320,000 after purchasing an additional 42,283 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Aurora Cannabis by 158.1% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 2,302,496 shares of the company’s stock worth $20,837,000 after purchasing an additional 1,410,446 shares during the last quarter. Finally, JW Asset Management LLC bought a new stake in shares of Aurora Cannabis during the fourth quarter worth $10,734,000. Institutional investors own 9.00% of the company’s stock.
Shares of Aurora Cannabis stock traded up $0.01 during trading on Monday, hitting $7.83. 6,117,283 shares of the stock traded hands, compared to its average volume of 23,143,816. The firm’s fifty day moving average is $7.90. Aurora Cannabis Inc has a 52-week low of $4.05 and a 52-week high of $12.52. The company has a current ratio of 2.37, a quick ratio of 1.98 and a debt-to-equity ratio of 0.10. The stock has a market cap of $8.02 billion, a price-to-earnings ratio of 65.25 and a beta of 2.50.
Several analysts have recently weighed in on the company. Zacks Investment Research upgraded Aurora Cannabis from a “sell” rating to a “hold” rating in a research report on Monday, May 20th. ValuEngine upgraded Aurora Cannabis from a “hold” rating to a “buy” rating in a research note on Tuesday, March 19th. TheStreet upgraded Aurora Cannabis from a “d+” rating to a “c” rating in a research note on Thursday, April 4th. GMP Securities upgraded Aurora Cannabis from a “hold” rating to a “buy” rating in a research note on Wednesday, March 13th. Finally, Bank of America started coverage on Aurora Cannabis in a research note on Wednesday, April 17th. They set a “buy” rating and a $11.00 price target on the stock. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $9.86.
Aurora Cannabis Company Profile
Aurora Cannabis Inc produces and distributes medical cannabis products. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution.
Read More: What is a CD ladder?
Receive News & Ratings for Aurora Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurora Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.